The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability
Open accessAbstract
P-glycoprotein (P-gp) is crucial in the active transport of various substrates with diverse structures out of cells, resulting in poor intestinal permeation and limited bioavailability following oral administration. P-gp inhibitors, including small molecule drugs, natural constituents, and pharmaceutically inert excipients, have been exploited to overcome P-gp efflux and enhance the oral absorption and bioavailability of many P-gp substrates. The co-administration of small molecule P-gp inhibitors with P-gp substrates can result in drug–drug interactions and increased side effects due to the pharmacological activity of these molecules. On the other hand, pharmaceutically inert excipients, including polymers, surfactants, and lipid-based excipients, are safe, pharmaceutically acceptable, and are not absorbed from the gut. Notably, they can be incorporated in pharmaceutical formulations to enhance drug solubility, absorption, and bioavailability due to the formulation itself and the P-gp inhibitory effects of the excipients. Different formulations with inherent P-gp inhibitory activity have been developed. These include micelles, emulsions, liposomes, solid lipid nanoparticles, polymeric nanoparticles, microspheres, dendrimers, and solid dispersions. They can bypass P-gp by different mechanisms related to their properties. In this review, we briefly introduce P-gp and P-gp inhibitors, and we extensively summarize the current development of oral drug delivery systems that can bypass and inhibit P-gp to improve the oral absorption and bioavailability of P-gp substrates. Since many drugs are limited by P-gp-mediated efflux, this review is helpful for designing suitable formulations of P-gp substrates to enhance their oral absorption and bioavailability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Sahay, G., Alakhova, D. Y., & Kabanov, A. V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.036 · Cited by 2,181
Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium
Mabbott, N. A., Donaldson, D. S., Ohno, H., Williams, I. R., & Mahajan, A. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.30 · Cited by 721 · cited 1×
“After the selective endocytosis of antigens, M cells transport them to intraepithelial macrophages and lymphocytes prior to their migration to lymph nodes [147].”
BackgroundAdapting liposomes for oral drug delivery
He, H., Lu, Y., Qi, J., Zhu, Q., Chen, Z., & Wu, W. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.06.005 · Cited by 663
Importance of P-glycoprotein at blood–tissue barriers
Fromm, M. F. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.06.002 · Cited by 592 · cited 1×
“, efflux) into the blood due to the activity of P-gp in the luminal membrane of endothelial cells [69].”
BackgroundMandal, A., Bisht, R., Rupenthal, I. D., & Mitra, A. K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.012 · Cited by 481 · cited 1×
“Several widely used techniques include solvent evaporation, oil-in-water emulsion, direct dissolution, dialysis, and freeze-drying [178].”
MethodLipid-Based Delivery Systems and Intestinal Lymphatic Drug Transport: A Mechanistic Update
Trevaskis, N. L., Charman, W. N., & Porter, C. J. H. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.09.007 · Cited by 442
Polymeric mixed micelles as nanomedicines: Achievements and perspectives
Cagel, M., Tesan, F. C., Bernabeu, E., Salgueiro, M. J., Zubillaga, M. B., Moretton, M. A., & Chiappetta, D. A. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.12.019 · Cited by 417
Review and analysis of FDA approved drugs using lipid-based formulations
Savla, R., Browne, J., Plassat, V., Wasan, K. M., & Wasan, E. K. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1342654 · Cited by 225
Everted gut sac model as a tool in pharmaceutical research: limitations and applications
Alam, M. A., Al-Jenoobi, F. I., & Al-mohizea, A. M. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2011.01391.x · Cited by 221
Cited by
Ghasemian, M., Kazeminava, F., Naseri, A., Mohebzadeh, S., Abbaszadeh, M., Kafil, H. S., & Ahmadian, Z. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115328 · Cited by 55
Solnier, J., Zhang, Y., Kuo, Y., Du, M., Roh, K., Gahler, R., Wood, S., & Chang, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112567 · Cited by 47
Metadata
- Authors
- Nguyen, T.-T.-L., Duong, V.-A., & Maeng, H.-J.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-07-20
- Volume
- 13
- Issue
- 7
- Pages
- 1103
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W3183743918
- Cited by
- 252
- References
- 15
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability. https://app.cochat.ai/papers/10.3390/pharmaceutics13071103
- The paper
- Nguyen, T.-T.-L., Duong, V.-A., & Maeng, H.-J. (2021). Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability. Pharmaceutics. https://doi.org/10.3390/pharmaceutics13071103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.